To include your compound in the COVID-19 Resource Center, submit it here.

Ublituximab: SPA received

TG Therapeutics said it received an SPA from FDA for a Phase III trial to compare IV ublituximab plus Imbruvica ibrutinib vs. Imbruvica alone in about 330 previously treated patients

Read the full 306 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE